“We are thrilled with the important clinical and operational progress recently achieved,” stated Dikla Czaczkes Akselbrad, PolyPid’s Chief Executive Officer. “With around 320 patients enrolled to date in SHIELD II, we look forward to the upcoming interim analysis and remain on track for the top-line data readout in the first quarter of next year. Moreover, in support of the further advancement of SHIELD II, we successfully completed a financing of up to $14 million that included participation from multiple U.S. life sciences-focused investors,” continued Ms. Czaczkes Akselbrad.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PYPD:
- PolyPid Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- PYPD Upcoming Earnings Report: What to Expect?
- PolyPid Secures Funding, Extends Runway for D-PLEX100 Trial
- PolyPid announces private placement of up to $14M in proceeds
- PolyPid Announces Private Placement for Up to $14 Million in Gross Proceeds